It is proposed a controlled research study aimed to evaluating and comparing the degree of skin satisfaction and comfort with cosmetic creams PB-011 and PB-012 in cancer patients who can develop a palmar and plantar peripheral polyneuropathy by treatment with chemotherapy. Both products are cosmetic creams derived from the cosmetic Nocisens® line (for the care of sensitive skin with atopic tendency). The hypothesis that is proposed to test is that the care with PB-011 or PB-012 of the sensitive skin associated with palmar and plantar peripheral polyneuropathy of cancer patients will increase their degree of satisfaction and skin comfort. This study is proposed in patients who are going to start chemotherapeutic treatment. The study conceives two populations: (i) population where PB-011 cream will be tested; and (ii) population that will test PB-012 cream. A sample size of 60 volunteers per population has been estimated to ensure statistical significance. As a qualitative relevant variable for patients, the degree of satisfaction and skin comfort of the volunteers will be assessed by means of questionnaires.

This proof-of-concept clinical trial is a multicenter, double-blind, randomized, placebo-controlled research project approved by the ethics committees of all participating hospitals. Medical oncologists have been responsible for recruiting volunteers, checking that they meet the inclusion and exclusion criteria, obtaining signed informed consent, completing the data collection booklet and collecting the occurrence of CIPN and the degree of CIPN, along with patient follow-up. Once informed consent has been signed, the patients are provided with a PB-011 or the PB-012 formulation and started a daily application on their hands. After the onset of sensory symptoms on hands and/or feet, participants applied the cream twice daily on hands and feet and began responding questionnaires to evaluate the severity of sensorial symptoms.

Inclusion Criteria:

• To be older than 18 year old
• To be able to complete questionnaires
• Give informed consent in writing
• Being able to apply the product under test by oneself
• To have been diagnosed with stage I-III primary cancer
• To have received a maximum of one treatment session with chemotherapy (derivatives of taxane, platinum or vincristines)
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
• Life expectancy greater than or equal to 6 months

Exclusion Criteria:

• Not being or having been treated with antidepressants, antiepileptics or HIV medication in the last 3 months
• Pre-existing peripheral neuropathies not related to chemotherapy treatment
• Pre-existing neurodegenerative or neuromuscular disease or history of stroke
• Family history of neuropathic diseases
• Having suffered in the last 6 months: myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization or class III/IV heart failure.
• Being receiving investigational treatment (being involved in a clinical trial
• Evidence or indication of metastasis affecting the Central Nervous System
• Use of immunosuppressive or immunomodulatory medication that may lead to immunodeficiencies
• Not being treated with topical palmar and/or plantar medication
• Known hypersensitivity to capsaicin
• Having reduced capacity for expression or response to forms
• Not have been under general anesthesia for at least one month before starting the study
• Complication of peripheral polyneuropathy symptoms that require the use of specific medication.

The study population was anyone over 18 years of age who met the inclusion and exclusion criteria and who was about to start chemotherapy treatment.

Data on the anonymised patients such as treatment, number of cycles, sex, age and morbidities during the study could be shared with reviwers or researchers.

From July of 2022 to July 2027

Upon request to Prospera Biotech, researchers and doctors will be able to access it. Additional information will be available for peer-reviewers.